阿卡波糖
生物信息学
对接(动物)
分子动力学
化学
背景(考古学)
酶动力学
药理学
酶
IC50型
体外
生物化学
动力学
药品
计算生物学
立体化学
活动站点
医学
生物
计算化学
基因
古生物学
护理部
物理
量子力学
作者
Saeed Mahmud Ullah,Muhammad Salman Waqas,Sobia Ahsan Halim,Imtiaz Ali Khan,Asaad Khalid,Ashraf N. Abdalla,Hafiz Antar Makeen,Aliya Ibrar,Ajmal Khan,Ahmed Al‐Harrasi
标识
DOI:10.1016/j.ijbiomac.2023.126227
摘要
Diabetes mellitus has been considered as a serious health problem worldwide due its high prevalence rate and associated complications. In this context, the current research work aims at exploring new structural leads for the treatment of a major metabolic disorder, diabetes mellitus type 2. The outcomes of our prior studies on a diverse set of triazolothiadiazole and triazolothiadiazine derivatives and their therapeutic potential, encouraged us to explore their anti-diabetic competency by targeting the key carbohydrate catabolic enzyme, α-glucosidase. Therefore, all these analogues were examined to reveal their contribution towards this severe metabolic issue. Interestingly, all the tested compounds (2a-2l and 3a-3p) exhibited several times more potent α-glucosidase inhibitory activities (IC50 in the range of 2.44-219.93 μM) as compared to marketed drug, acarbose (IC50 = 873.34 ± 1.67 μM). Furthermore, their mechanism of action was investigated through in vitro kinetics studies which revealed compounds 3a, 3d, 3o, and 2k as competitive inhibitors, and 3f as a mixed type inhibitor of α-glucosidase. In addition, in silico molecular docking and molecular dynamics simulations were applied to observe the mode of interaction of the active hits within the binding pocket of α-glucosidase. Both docking and simulation results favored our in vitro mechanistic analysis.
科研通智能强力驱动
Strongly Powered by AbleSci AI